Cohort1: AGN211745_dose level 1
|
Administration route |
intravitreal injection |
Dosage |
AGN211745, 100mg |
Pts |
26 |
Age |
Adult, Older_Adult |
References |
PMID:
20609706
|
|
Cohort2: AGN211745_dose level 2
|
Administration route |
intravitreal injection |
Dosage |
AGN211745, 200mg |
Pts |
26 |
Age |
Adult, Older_Adult |
References |
PMID:
20609706
|
|
Cohort3: AGN211745_dose level 3
|
Administration route |
intravitreal injection |
Dosage |
AGN211745, 400mg |
Pts |
26 |
Age |
Adult, Older_Adult |
References |
PMID:
20609706
|
|
Cohort4: AGN211745_dose level 4
|
Administration route |
intravitreal injection |
Dosage |
AGN211745, 800mg |
Pts |
26 |
Age |
Adult, Older_Adult |
References |
PMID:
20609706
|
|
Cohort5: AGN211745_dose level 5
|
Administration route |
intravitreal injection |
Dosage |
AGN211745, 1200mg |
Pts |
26 |
Age |
Adult, Older_Adult |
References |
PMID:
20609706
|
|
Cohort6: AGN211745_dose level 6
|
Administration route |
intravitreal injection |
Dosage |
AGN211745, 1600mg |
Pts |
26 |
Age |
Adult, Older_Adult |
References |
PMID:
20609706
|
|